Striking dichotomy in outcome of MYCN‐amplified neuroblastoma in the contemporary era

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|13|2050-2059

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.13, 2014-07, pp. : 2050-2059

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Genomic markers for neuroblastoma risk estimation: superseding tumor stage, age and MYCN?

By Oberthuer André  

Biomarkers in Medicine, Vol. 7, Iss. 6, 2013-12 ,pp. : 905-908

Future Medicine

Access to resources Recommend Favorite

Detection of MYCN Amplification and Chromosome 1p36 Loss in Neuroblastoma by cDNA Microarray Comparative Genomic Hybridization

By Paola Scaruffi   Stefano Parodi  

Molecular Diagnosis, Vol. 8, Iss. 2, 2004-01 ,pp. : 93-100

Adis International

Access to resources Recommend Favorite

MYCN overexpression is associated with unbalanced copy number gain, altered nuclear location, and overexpression of chromosome arm 17q genes in neuroblastoma tumors and cell lines

By  

GENES, CHROMOSOMES AND CANCER, Vol. 54, Iss. 10, 2015-10 ,pp. : 616-628

John Wiley & Sons Inc

Access to resources Recommend Favorite

Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Oncology Group

By  

CANCER, Vol. 119, Iss. 20, 2013-10 ,pp. : 3718-3726

John Wiley & Sons Inc

Access to resources Recommend Favorite

Management and Outcome of Acute Myocardial Infarction in Older Patients in the Thrombolytic Era

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 47, Iss. 3, 1999-03 ,pp. : 291-294

John Wiley & Sons Inc

Access to resources Recommend Favorite